Contribute Try STAT+ Today

TG Therapeutics (TGTX) on Tuesday delayed yet again the readout from its most important blood cancer clinical trial. And like the previous delay of study results disclosed in September 2018, the biotech’s CEO is papering over the very real risk of failure.

Final results from a Phase 3 clinical trial called UNITY-CLL had been expected to read out in the first quarter, based on the company’s own guidance. On Tuesday, CEO Mike Weiss copped to a problem: The required number of tumor progression events needed to analyze the study haven’t occurred as expected.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • You’re definitely right that long-delayed trials is usually a bad sign, likely from the control arm doing better than expected. However, this definitely isn’t always the case. Most recently Karyopharm and the BOSTON trial benefited from this, with the treatment arm doing better than the comparator.

  • Since you’ve never spoken to the company, it may be better if you do so before writing an article. You may be more informed that way.

Comments are closed.